Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Leukemia, Myeloid, Acute 2Thrombocythemia, Essential 1Small Cell Lung Carcinoma 1Recurrence 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lung Neoplasms 1GATA2 Deficiency 1Carcinoma, Neuroendocrine 1

Interventions

Carboplatin 47Etoposide 46durvalumab 28atezolizumab 27Cisplatin 21Topotecan 19pembrolizumab 15PM 01183 15Nivolumab 12Specimen Handling 11Drug Therapy 10anlotinib 9Radiotherapy 9Paclitaxel 9Temozolomide 8Magnetic Resonance Spectroscopy 8AMG 757 8Radiosurgery 7Platinum 7Irinotecan 7toripalimab 6olaparib 6Biopsy 6Ipilimumab 5Injections 5Docetaxel 5Bevacizumab 5trilaciclib 4tremelimumab 4tislelizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × iadademstat × 1 year × Clear all
NCT05420636 2025-07-30

Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

Fox Chase Cancer Center

Phase 2 Terminated
20 enrolled
EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡